Patient Access Support Resources

Pharmacy Locator

ZORYVE® IT

RELIEVE IT

The power and versatility to be your go-to topical¹

Foam 0.3%
For age 12+

Delivers powerful skin clearance and rapid itch relief, from head to toe¹

Well tolerated and safe for any skin and hair type^1,2

Simple, once-daily treatment¹

Not a steroid¹

POWERFUL SKIN CLEARANCE ANYWHERE DISEASE PRESENTS^1,3

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.¹

SCALP*^†

63%

of patients achieved S-IGA Success at Week 8 using ZORYVE foam 0.3% (n=481) vs 21% with vehicle (n=255)

P<0.0001 vs vehicle, nominal.

BODY*^‡

42%

of patients achieved B-IGA Success at Week 8 using ZORYVE foam 0.3% (n=481) vs 15% with vehicle (n=255)

P<0.0001 vs vehicle, nominal.

Data are pooled analyses of the ARRECTOR and Trial 204 studies.

^†

Measured by S-IGA Success=Achievement of an S-IGA score of Clear (0) or Almost Clear (1) plus a ≥2-grade improvement from baseline.

^‡

Measured by B-IGA Success=Achievement of a B-IGA score of Clear (0) or Almost Clear (1) plus a ≥2-grade improvement from baseline.

Pivotal Study Design

Two multicenter, randomized, parallel, double-blind, vehicle-controlled studies (ARRECTOR and Trial 204) evaluated 736 participants with plaque psoriasis treated with ZORYVE foam 0.3% or vehicle once daily for 8 weeks. ZORYVE = 481, vehicle = 255.

Primary endpoints were S-IGA Success at Week 8 in both studies, and B-IGA Success at Week 8 in ARRECTOR. Key secondary endpoints were B-IGA Success at Week 8 in Trial 204, SI-NRS Success at Week 8 in ARRECTOR: ZORYVE foam = 203, vehicle = 123, and WI-NRS Success at Week 8 in ARRECTOR: ZORYVE foam = 203, vehicle = 110.^1,4,5

RAPID ITCH RELIEF FROM HEAD TO TOE^1,4

In ARRECTOR

SCALP^§

Line graph showing SI-NRS success over 8 weeks. ZORYVE foam 0.3% outperforms Vehicle, with 65% of patients achieving success by Week 8 vs. 30% for Vehicle.

P<0.001 vs vehicle at all time points.

BODY^II

Line graph showing WI-NRS success over 8 weeks. ZORYVE foam 0.3% leads to higher success (63% at Week 8) compared to Vehicle (30%).

P<0.001 vs vehicle at all time points, nominal at Weeks 2 and 4.

Greater itch improvement experienced within 24 hours

after first application across the scalp and body with ZORYVE vs. vehicle (both SI-NRS and WI-NRS; P<0.05)^4⁋#

^§

Measured by SI-NRS Success=Achievement of ≥4-point improvement from baseline in patients with baseline SI-NRS ≥4. SI-NRS: 0 (no itch) to 10 (worst imaginable itch).

^||

Measured by WI-NRS Success=Achievement of ≥4-point improvement from baseline in patients with baseline WI-NRS ≥4. WI-NRS: 0 (no itch) to 10 (worst imaginable itch).

^⁋

Data from ARRECTOR study only.

Measured by change from first application in daily SI-NRS/WI-NRS. P-value for WI-NRS is nominal.

RELIABLE RESULTS PATIENTS CAN SEE AND FEEL³

SCALP

Age 56, Male

BASELINE S-IGA=4

WEEK 8 S-IGA=1

TRUNK

Age 59, Female

BASELINE B-IGA=3

WEEK 8 B-IGA=0

LEG

Age 56, Male

BASELINE B-IGA=2

WEEK 8 B-IGA=1

Actual clinical trial patients.

WELL TOLERATED AND SAFE FOR ANY DURATION OR BODY LOCATION¹

Adverse reactions reported in ≥1% of patients treated with ZORYVE for 8 weeks

Headache

3.1%

1.2%

Diarrhea

2.5%

1.6%

Nausea

1.7%

0.0%

Nasopharyngitis

1.3%

0.8%

Low rates of stinging or burning (0.4%)^6**

Not associated with folliculitis, atrophy, striae or HPA-axis suppression¹

Low rate of discontinuation due to adverse events (2.1%)³

^**

Low rates of hot, tingling/stinging sensation reported in patient-rated tolerability assessments 10–15 minutes after first application: In ARRECTOR 0.4% for ZORYVE foam (n=280) vs 1.4% for vehicle (n=148).⁶

ZORYVE foam is designed with purpose and the patient in mind

Simple foam application anywhere on the body, including difficult-to-treat scalp and other hair-bearing areas.